MedTrace Logo

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

NCT03262389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-03-16

Study results available
· View outcomes & findings →

Summary

Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

Conditions

Interventions

DRUG

Fludeoxyglucose PET CT

Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).

DRUG

Sodium Acetate C11 PET CT

Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).

DRUG

Fludeoxyglucose PET MRI

Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).

DRUG

Sodium Acetate C11 PET MRI

Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).

Sponsors & Collaborators

  • Michael C Roarke, MD

    lead OTHER

Principal Investigators

  • Michael C Roarke · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-19
Primary Completion
2019-11-23
Completion
2019-11-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03262389 on ClinicalTrials.gov